DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[DOCKET NO. FDA–2013–N–0297]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Prevention of Salmonella Enteritidis in Shell Eggs During Production—Recordkeeping and Registration

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled, “Prevention of Salmonella Enteritidis in Shell Eggs During Production—Recordkeeping and Registration,” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 1350 Piccard Dr., P50–400B, Rockville, MD 20850, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: On May 20, 2013, the Agency submitted a proposed collection of information entitled “Prevention of Salmonella Enteritidis in Shell Eggs During Production—Recordkeeping and Registration,” to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0660. The approval expires on August 31, 2016. A copy of the supporting statement for this information collection is available on the Internet at http://www.reginfo.gov/public/do/PRAMain.


Leslie Kux,
Assistant Commissioner for Policy.

[FR Doc. 2013–21680 Filed 9–5–13; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[DOCKET NO. FDA–2013–N–0579]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Recordkeeping Requirements for Medicated Feed Mill License Application

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled, “Medicated Feed Mill License Application,” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 1350 Piccard Dr., P50–400B, Rockville, MD 20850, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: On May 15, 2013, the Agency submitted a proposed collection of information entitled “Medicated Feed Mill License Application,” to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0337. The approval expires on August 31, 2016. A copy of the supporting statement for this information collection is available on the Internet at http://www.reginfo.gov/public/do/PRAMain.


Leslie Kux,
Assistant Commissioner for Policy.

[FR Doc. 2013–21681 Filed 9–5–13; 8:45 am]

BILLING CODE 4160–01–P
Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Paul Loebach, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 2262, Silver Spring, MD 20993–0002, email: edrls@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft guidance for industry entitled “Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration.” In July 2012, FDASIA was signed into law (Pub. L. 112–144). Sections 701 and 702 of FDASIA direct the Secretary to specify the UFI system for registration of domestic and foreign drug establishments. Once the UFI system is specified, section 510 of the FD&C Act, as amended, requires that each initial and annual drug establishment registration include a UFI (21 U.S.C. 360(b), (c), and (i)). This draft guidance reflects the Agency’s current thinking in light of data standards, information technology, and information management resources. As these variables change over time, FDA may revisit this guidance.

This draft guidance is intended solely to address the provisions in sections 701 and 702 of FDASIA. Although section 703 of FDASIA mandates the use of the same UFI system specified for drug establishment registration to identify excipient manufacturers in product listings, this guidance does not address implementation of section 703 of FDASIA.

This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the Agency’s current thinking on specification of the UFI system for drug establishment registration. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

Under the Paperwork Reduction Act of 1995 (the PRA) (44 U.S.C. 3501–3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information that they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA, 44 U.S.C. 3506(c)(2)(A), requires Federal Agencies to provide a 60-day notice in the Federal Register for each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing this notice of the proposed collection of information set forth in this document. With respect to the collection of information associated with this draft guidance, FDA invites comments on the following topics: (1) Whether the proposed information collected is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimated burden of the proposed information collected, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information collected; and (4) ways to minimize the burden of information collected on the respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Sections 701 and 702 of FDASIA direct the Secretary to specify the UFI system for registration of domestic and foreign drug establishments. Once the UFI system is specified, section 510 of the FD&C Act, as amended, requires that each initial and annual drug establishment registration include a UFI. The draft guidance specifies the UFI system as follows. At this time, FDA’s preferred UFI for a drug establishment is the Data Universal Numbering System D–U–N–S (DUNS) number, assigned and managed by Dun and Bradstreet. The DUNS number is the Federal Government’s preferred UFI for a drug establishment, and is not expected to have any impact on the previously approved collection of information.

The draft guidance addressed in this notice, “Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration,” when finalized, would modify the currently approved information collections associated with drug establishment registration, consistent with subsequent statutory enactment. In July 2012, Congress enacted FDASIA, sections 701 and 702 of which direct the Secretary to specify the UFI system for registration of domestic and foreign drug establishments. Once the UFI system is specified, section 510 of the FD&C Act, as amended, requires that each initial and annual drug establishment registration include a UFI. The draft guidance specifies the UFI system as follows. At this time, FDA’s preferred UFI for a drug establishment is the Data Universal Numbering System D–U–N–S (DUNS) number, assigned and managed by Dun and Bradstreet. The DUNS number is the Federal Government’s preferred UFI for a drug establishment, and is not expected to have any impact on the previously approved collection of information.

www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072339.pdf, under OMB control number 0910–0045. The Food and Drug Administration Amendments Act of 2007 (Pub. L. 110–85) required that drug establishment registration and drug listing information must be submitted electronically unless a waiver is granted. As part of its recommendations to facilitate electronic submission of drug establishment registration information, as required by statute, the 2009 guidance explained that FDA is adopting the use of extensible markup language (XML) files in a standard structured product labeling (SPL) format for the electronic submission of drug establishment registration and drug listing information. The 2009 guidance also explained that the automated submission process functions most efficiently and effectively when the information is provided in a standardized format with defined code sets and codes. In addition, the 2009 guidance requested, among other things, the electronic submission of a site-specific DUNS number for each entity as part of the registration information submitted electronically. In FDA’s experience, all firms currently registered with FDA under section 510 of the FD&C Act and part 207 have submitted their DUNS number as requested in the 2009 guidance.

The draft guidance addressed in this notice, “Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration,” when finalized, would modify the currently approved information collections associated with drug establishment registration, consistent with subsequent statutory enactment. In July 2012, Congress enacted FDASIA, sections 701 and 702 of which direct the Secretary to specify the UFI system for registration of domestic and foreign drug establishments. Once the UFI system is specified, section 510 of the FD&C Act, as amended, requires that each initial and annual drug establishment registration include a UFI. The draft guidance specifies the UFI system as follows. At this time, FDA’s preferred UFI for a drug establishment is the Data Universal Numbering System D–U–N–S (DUNS) number, assigned and managed by Dun and Bradstreet. The DUNS number is the Federal Government’s preferred UFI for a drug establishment, and is not expected to have any impact on the previously approved collection of information.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Food and Drug Administration
[Docket No. FDA–2013–N–0001]

Food and Drug Administration/
American Academy of Ophthalmology
Workshop on Developing Novel
Endpoints for Premium Intraocular
Lenses; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

The Food and Drug Administration (FDA) is announcing the following public workshop entitled “FDA/ American Academy of Ophthalmology (AAO) Workshop on Developing Novel Endpoints for Premium Intraocular Lenses.” The main topic of this workshop is the current challenges in the assessment of innovative intraocular lens (IOL) designs with a focus on endpoint methodologies used in evaluating IOL safety and effectiveness. Experts in subjects ranging from patient reported outcomes to objective measures of accommodation will give talks on the latest developments in the field. Participants will then engage in indepth discussions of the pros and cons of various methods used to assess premium IOLs and work to devise a plan to further promote innovation in this device area. The primary goal of the workshop is to improve the regulatory science for evaluating premium IOLs, which in turn may enhance the efficiency with which safe and effective premium IOLs get to the market.

Date and Time: The public workshop will be held on October 11, 2013, from 8:30 a.m. to 5:30 p.m. Materials may be picked up starting at 7:30 a.m.

Location: The public workshop will be held at FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD 20993. Entrance for the public workshop participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to http://www.fda.gov/AboutFDA/ WorkingatFDA/BuildingsandFacilities/ WhiteOakCampusInformation/ ucm241740.htm.

Contact: Michelle Tarver, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 2504, Silver Spring, MD 20993; 301–796–5620, FAX: 301–847–8126, email: michelle.tarver@fda.hhs.gov.

Registration: AAO will charge a registration fee to cover its share of the expenses associated with the workshop. The registration fee is $250 for Academy members and $400 for non-members. Registration is available on a first-come, first-served basis. Persons interested in attending this public workshop must register online. The deadline for online registration is October 10, 2013, at 5 p.m. EDT. There will be no onsite registration on the day of the public workshop. Early registration is recommended because facilities are limited and, therefore, FDA may limit the number of participants from each organization.

To register for the public workshop, please visit the AAO Web site (www.aaa.org/IOLworkshop). Those interested in attending but unable to access the electronic registration site should fax the PDF form on the AAO Web site (http://www.aaa.org/meetings/upload/FDA_iol_workshop_reg.pdf) to 415–561–8575. Those without Internet access should contact AAO Customer Service to register at 451–561–8540 or 866–561–8558 (toll free). Please provide complete contact information for each attendee, including name, title, affiliation, address, email, and telephone number. If there are any questions with registration, please contact the AAO administrative offices at 415–561–8540. Registrants will receive confirmation after they have been accepted. You will be notified if you are on a waiting list.

Food and beverages will be available for purchase by participants during the workshop breaks.

If you need special accommodations due to a disability, please contact Ms. Susan Monahan at susan.monahan@fda.hhs.gov or 301–796–5661 no later than September 30, 2013.

For more information on the workshop, please see the FDA’s Medical Devices News & Events—Workshops & Conferences calendar at http://www.fda.gov/MedicalDevices/ NewsEvents/WorkshopsConferences/ default.htm. (Select this public workshop from the posted events list.)

Streaming Webcast of the Public Workshop: The morning session but not the afternoon session of this public workshop will also be Webcast. Persons interested in viewing the Webcast must register online by 5 p.m. EDT, September 27, 2013. Early registration is recommended because Webcast connections are limited. Organizations are requested to register all participants, but to view using one connection per location. Webcast participants will be sent technical system requirements after registration and will be sent connection

Persons with access to the Internet may obtain the document at http://www.fda.gov/Drugs/Guidance

Endpoints for Premium Intraocular
Lenses."

The main topic of this
workshop is the current
difficulties in the
assessment of innovative
IOL designs with a focus
on endpoint methodologies
used in evaluating IOL safety
and effectiveness.

Experts in subjects ranging
from patient reported
outcomes to objective
measures of accommodation
will give talks on the latest
developments in the field.

Participants will then engage
in indepth discussions of the
pros and cons of various
methods used to assess
premium IOLs and work to
deive a plan to further
promote innovation in this
device area.

The primary goal of the
workshop is to improve the
regulatory science for evaluating
premium IOLs, which in turn
may enhance the efficiency
with which safe and effective
premium IOLs get to the market.

Date and Time: The public
workshop will be held on
October 11, 2013, from
8:30 a.m. to 5:30 p.m.
Materials may be picked
up starting at 7:30 a.m.

Location: The public
workshop will be held at
FDA White Oak Campus,
10903 New Hampshire
Ave., Bldg. 31 Conference
Center, the Great Room
(rm. 1503), Silver Spring,
MD 20993. Entrance for
the public workshop
participants (non-FDA
employees) is through
Building 1 where routine
security check procedures
will be performed. For parking
and security information,
please refer to http://www.
fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.

Contact: Michelle Tarver,
Center for Devices and
Radiological Health, Food
and Drug Administration,
10903 New Hampshire Ave.,
Bldg. 66, Rm. 2504, Silver
Spring, MD 20993; 301–796–
5620, FAX: 301–847–8126,
email: michelle.tarver@fda.
hhs.gov.

Registration: AAO will
charge a registration fee to
cover its share of the
expenses associated with
the workshop. The
registration fee is $250 for
Academy members and
$400 for non-members.
Registration is available
on a first-come, first-

served basis. Persons
interested in attending this
public workshop must register
online. The deadline for online
registration is October 10,
2013, at 5 p.m. EDT. There
will be no onsite registration
on the day of the public
workshop. Early registration
is recommended because
facilities are limited and,
therefore, FDA may limit
the number of participants
from each organization.

To register for the
public workshop,
please visit the AAO Web site
(www.aaa.org/IOLworkshop).
Those interested in
attending but unable to
access the electronic
registration site should
fax the PDF form on the AAO
Web site (http://www.aaa.org/meetings/uploads/FDA_iol_workshop_reg.pdf) to
415–561–8575. Those without
Internet access should contact
AAO Customer Service to
register at 451–561–8540 or
866–561–8558 (toll free). Please
provide complete contact
information for each
attendee, including name,
title, affiliation, address, email,
and telephone number. If there are
any questions with registration,
please contact the AAO administrative
offices at 415–561–8540.
Registrants will receive
confirmation after they have
been accepted. You will be notified
if you are on a waiting list.

Food and beverages will be available
for purchase by participants
during the workshop
breaks.

If you need special accommodations
due to a disability, please contact Ms.
Susan Monahan at susan.
monahan@fda.hhs.gov or
301–796–5661 no later than
September 30, 2013.

For more information on the
workshop, please see the FDA’s Medical
Devices News & Events—Workshops &

Conferences calendar at
http://www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
default.htm. (Select this public
workshop from the posted
events list.)

Streaming Webcast of the Public
Workshop: The morning session but
not the afternoon session of this public
workshop will also be Webcast. Persons
interested in viewing the Webcast
must register online by 5 p.m. EDT,
September 27, 2013. Early registration
is recommended because
Webcast connections are
limited. Organizations are
requested to register all
participants, but to view
using one connection per
location. Webcast participants
will be sent technical system
requirements after
registration and will be sent
connection.